Efficacy, outcomes, and cost-effectiveness of desensitization using ivig and rituximab

Transplantation

Volumn 95, Issue 6, 2013, Pages 852-858

  Vo, Ashley A ^a   Petrozzino, Jeffrey ^b,c   Yeung, Kai ^a   Sinha, Aditi ^d   Kahwaji, Joseph ^a   Peng, Alice ^a   Villicana, Rafael ^a   MacKowiak, John ^e   Jordan, Stanley C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Compara Biomedical ^*  (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e Center for Outcomes Research   (United States)

Author keywords

Acute antibody mediated rejection; Acute cellYmediated rejection; Broadly HLA sensitized; Desensitization; Dialysis cost; Economic cost model; IVIG; Kidney transplant outcomes; Markov model; Rituximab

Indexed keywords

HLA ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB; ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DESENSITIZATION; DIALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; SYNDROME DELINEATION; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; HISTOCOMPATIBILITY TEST; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT SURVIVAL; HEALTH CARE COSTS; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84877600533     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182802f88     Document Type: Article

References (30)

1. U.S. Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Chapter 6, Cost of Chronic Kidney Disease pp. 91Y100. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011.
2. Fields R. In: Dialysis, Life Saving Care @ Great Risk and Cost. ProPublica. November 9, 2010.
3. United Network for Organ Sharing (UNOS). Available at: http://unos.org [accessed 2012 Jun].
4. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520Y2531.
5. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388Y399.
6. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68Y74.
7. Vo A, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
8. Vo A, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
9. Shehata N, Palda V, Meyer R, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transf Med Rev 2010; 24: 7.
10. Montgomery RA, Lonze B, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318.
11. Reinsmoen N, Lai C-H, Vo A, et al. Evolving paradigms for desensi-tization in managing broadly HLA sensitized transplant candidates. Discov Med 2012; 13: 267.
12. Marfo K, Lu A, Ling M, et al. Desensitization protocols and their outcomes. Clin J Am Soc Nephrol 2011; 6: 922, 2011.
13. Lai CH, Cao K, Ong G, et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011; 92: 48.
14. Rehman S, Meier-Kriesche HU, Scornik J. Use of intravenous immune globulin and rituximab for desensitization of highly human leukocyte antigen-sensitized patients awaiting kidney transplantation. Transplantation 2010; 90: 932.
15. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012; 94: 345.
16. Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012; 94: 165.
17. Based on OPTN data as of 29 Sep 12.
18. Gold MR, Siegel JE, Russell LB, et al, eds. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996: 232Y233.
19. Heitman SJ, Hilsden RJ, Au F, et al. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med 2010; 7: e1000370. doi:10.1371/journal.pmed.1000370
20. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896.
21. Scientific Registry of Transplant Recipients (SRTR). Available at: http://SRTR.org [accessed 2012].
22. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin (IVIG) as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 Trial. J Am Soc Nephrol 2004; 15: 3256.
23. Vo A, Cam V, Toyoda M, et al. Safety and adverse event profiles of IVIG products used for immunomodulation: a single center experience. Clin J Am Soc Nephrol 2006; 1: 844.
24. Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after highdose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Soc Nephrol 2009; 4: 1993.
25. Kahwaji J, Tong C, Jordan SC, et al. Rituximab: an emerging therapeutic agent for kidney transplantation. Transplant Res Risk Manage 2009: 15.
26. Kahwaji J, Sinha A, Toyoda M, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6: 2894.
27. Vo A, Weschler EA, Wang J, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008; 8: 144.
28. U.S. Bureau of Labor Statistics. Consumer price index. Available at: http://bls.gov/data/[cited 2011 May 30].
29. Centers for Medicare & Medicaid Services. Average sales price drug pricing files. Available at: https://www.cms.gov/McrPartBDrugAvgSales Price/01a18-2011ASPFiles.asp [accessed 2011 Apr].
30. Agency for Healthcare Research and Quality. HCUPnet nationwide inpatient sample. Rockville: Agency for Healthcare Research and Quality, 2011.